Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.
about
Development of biomarkers to optimize pediatric patient management: what makes children different?Developmental pharmacokinetics in pediatric populationsPharmacogenetics-based warfarin dosing in childrenAdverse Drug Reactions in Children: The Double-Edged Sword of Therapeutics.Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiationPrediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences.Characterizing variability in warfarin dose requirements in children using modelling and simulation.Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.Developmental and pediatric pharmacogenomics.Characterizing the impact of development on the dose-exposure-response relationship: challenge or opportunity?Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin.How children's responses to drugs differ from adults.Modelling approaches to dose estimation in childrenVitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirementEffect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenPharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations.Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithmsPopulation pharmacokinetics of intravenous pantoprazole in paediatric intensive care patientsHormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence.Warfarin pharmacogenomics in children.Optimizing pediatric dosing: a developmental pharmacologic approach.Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children.Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients.Personalised dosing of medicines for children.Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling.Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients.Long-term effects of ABCB1 and SXR SNPs on the systemic exposure to cyclosporine in pediatric kidney transplant patients.Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans.UNUSUAL WARFARIN DOSE TO ACHIEVE THERAPEUTIC INR IN A 4-MONTH OLD CHILD: NON-GENETICS RISK FACTORS ARE STILL A CHALLENGE.Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid.Developmental changes of aldehyde oxidase activity in young Japanese children.Developmental changes of fluconazole clearance in neonates and infants in relation to ontogeny of glomerular filtration rate: literature review and data analysis.
P2860
Q26822946-CCD018F5-AEB9-43A1-993F-AAC4CC82F483Q27002933-13289307-D186-47D3-967A-D2F5D0698E3BQ27008320-85A99EA5-EC53-4CA1-A640-13B880C535F1Q30235268-CC452563-EEFE-4E8F-8771-B102D3CE0F84Q31042226-D372A09C-850A-483A-87DF-EED71CA463E4Q31049674-BBCC8EA8-112B-42ED-AF8A-4974F4E9473FQ34209582-213302E2-9105-4BD6-BB80-CA807500E3BDQ34443184-E11CB23E-8241-4BA5-9701-B3085DBF153FQ35116112-F996979C-6EF7-4CDA-8A8C-2A142B9FD49BQ35124112-46B5F17C-D986-4749-BC50-5CC8F2DF6418Q35204081-ABD8B751-9985-4083-AE9F-18DC718D05B5Q35827035-CCDECB01-8845-453C-94D2-45E5AF72198CQ35827045-F652F335-7B1D-4EEE-879A-DA07ED9D0BA6Q36062295-DC94C61E-E5EF-4337-A43F-81FB77FE0927Q36322918-FF7F395C-5C21-48F1-BA5F-BF8CB27F2748Q36425083-A3B9F33A-A308-40C1-93BB-9108AA465B03Q36544972-5AFD5FA6-1024-4577-A23B-4706830A234EQ36836979-454ECF61-1F43-4B63-98C9-158C39AD9D17Q37161518-4523B119-A0F3-4E3F-BDC7-16F90FCA954AQ37198678-5D63E008-7023-40D1-8E4D-EAC77DA09315Q37205695-DC1114B5-1B61-4A85-B3D9-73E49F1F0568Q37498862-33FF93E8-6FC2-4E3E-90CD-07B33DE48AE7Q37872786-157AF765-2D39-4843-84D0-F2CA09CB5A5BQ37883008-AFA33B15-F32C-4AAC-846B-1B4A3768C97CQ38116770-AAE8B420-B596-4962-A400-3423058F22F3Q38749764-3538E670-624F-45CA-B49F-9F5DA88B1AD7Q39870288-4A234C4F-9DFD-4393-9630-84C31012309DQ40772216-BB303337-D931-4DE4-9468-5CC2E628C1F1Q44367614-E408E86D-3EA9-4F6A-BE91-558FF3B490E1Q44839090-0115F809-37E4-4DD8-A76F-C160EC103E19Q45894333-16F2DA5A-24BB-4D3B-B958-1011A92B301AQ47160906-CD04A1DC-8D34-4F2C-A2A5-A99ABB9DED00Q50972464-F0532184-6D56-4D52-84C2-074DC0C5909DQ51991155-1F08E163-DFA3-4C1D-8AA3-2F5789784FE9Q54250407-7E370E95-1F28-4457-9077-A5F851A89A03
P2860
Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Developmental changes in pharm ...... ntiomers in Japanese children.
@en
Developmental changes in pharm ...... ntiomers in Japanese children.
@nl
type
label
Developmental changes in pharm ...... ntiomers in Japanese children.
@en
Developmental changes in pharm ...... ntiomers in Japanese children.
@nl
prefLabel
Developmental changes in pharm ...... ntiomers in Japanese children.
@en
Developmental changes in pharm ...... ntiomers in Japanese children.
@nl
P2093
P356
P1476
Developmental changes in pharm ...... ntiomers in Japanese children.
@en
P2093
Ishikawa S
Kanamori M
Nishigaki Y
Takahashi H
P304
P356
10.1067/MCP.2000.110977
P407
P577
2000-11-01T00:00:00Z